NexCAR19 vs Qartemi: How the Two Indian CAR-T Products Compare

Different slices of B-cell cancer. NexCAR19 is approved for relapsed or refractory B-cell non-Hodgkin lymphoma and for B-cell acute lymphoblastic leukaemia, from age 15, after at least one prior line of therapy. Qartemi is approved for adult relapsed or refractory B-cell non-Hodgkin lymphoma. Neither treats solid tumours or multiple myeloma.

That single difference decides more cases than anything else on this page. A 16-year-old whose B-cell acute lymphoblastic leukaemia has relapsed has one approved Indian option, not a choice between two. An adult with relapsed diffuse large B-cell lymphoma may, in principle, be considered for either.

Approval details follow CDSCO regulatory information and the manufacturers’ published product information, read in August 2026. Approved indications can be extended over time, so the current label should be confirmed with the treating centre rather than assumed from this page.

The two published figures sit close together. ImmunoACT said NexCAR19 was expected to cost about US$50,000, and Indian reporting has described roughly ₹30–40 lakh. Immuneel said Qartemi was expected to cost about US$60,000 per dose, reported at launch at ₹35–50 lakh. Both are product prices, indicative as of August 2026.

Price is where most families start, and it is the wrong place to start, because the two products are rarely competing for the same patient. Where they are, the difference between the announced figures is small next to the difference between one admission and another. Still, the numbers matter, so here is what has actually been published.

Two families quoted the same product price can still end up with very different totals, because the variable is not the product. It is how the admission goes. A course with no complications and one that needs a week in intensive care are not the same episode of care, and no announced price predicts which you will have.

The funding side is worth understanding before the estimate arrives. NexCAR19 Cost and How Families Pay for It sets out the routes Indian families actually use, and insurance and scheme coverage for CAR-T by product covers what policies and government schemes have paid for so far.

Every figure above is a manufacturer announcement or a figure reported in published sources, named and dated, and is indicative only as of August 2026. These are product prices, not the cost of a course of care. CION Cancer Clinics does not price, quote or supply either product, and only the treating centre can issue a written estimate for one patient.

At licensed cell therapy centres, not at every cancer hospital. ImmunoACT describes a network of more than 80 authorised hospitals for NexCAR19 across India. Qartemi has been reported as available at more than 30 hospitals in over 10 cities. Both figures are company-stated, both change, and both should be confirmed directly.

A centre qualifies for this work only if it has apheresis facilities to collect the T cells, a qualified cell therapy unit, and intensive care on site. That last requirement is not procedural. Cytokine release syndrome and neurological toxicity can develop quickly in the days after infusion, and the centre has to be able to manage them without transferring the patient.

Manufacturing is domestic for both products. ImmunoACT manufactures in Navi Mumbai and describes a turnaround of about 18 days between collection and release, a company-stated figure. Immuneel manufactures in Bengaluru. Because neither product crosses a border in either direction, the weeks that international CAR-T adds for shipping frozen cells out and back do not apply here.

Immuneel has named hospital partners including Narayana Health, Apollo Hospitals, Christian Medical College and Manipal Hospitals. ImmunoACT publishes its own authorised-centre list. Neither list is fixed, and neither is a substitute for asking a specific hospital what it is authorised for today. Where CAR-T therapy is available in India sets out how to identify a licensed centre and what a referral to one involves.

Neither product is an option for the great majority of people with cancer in India, and comparing them is beside the point until eligibility has been settled. Both are CD19-directed, which confines them to B-cell malignancies. Solid tumours — breast, lung, head and neck, colorectal, cervical and the rest — are not treated with either product. Multiple myeloma is treated with BCMA-directed CAR-T products, a different class with no approved Indian equivalent as of August 2026, which is covered in CAR-T for myeloma in India.

The two products also exclude different people from each other. Qartemi’s approval is for adults with B-cell non-Hodgkin lymphoma, so it does not cover B-cell acute lymphoblastic leukaemia, and it does not cover a patient under 18. NexCAR19’s approval starts at age 15 and covers both lymphoma and B-ALL, so it does not cover a younger child outside a trial. Where a diagnosis and an age point to only one product, there is no comparison to make.

Even inside an approved indication, a haematologist weighs far more than the diagnosis: organ function, performance status, whether the disease can be held steady during the weeks of manufacturing, active infection, central nervous system involvement, prior treatment lines, and whether the family can stay near a licensed centre for several weeks. Any of those can rule CAR-T out for someone whose diagnosis appears on the label. NexCAR19 eligibility goes through that assessment in detail.

This page is also not a recommendation to use either product, a quality ranking between two manufacturers, or an offer to supply anything. CION Cancer Clinics does not provide, administer, stock or arrange CAR-T or any other cell therapy. Whether CAR-T applies to a particular patient, and which product and centre would be appropriate, is a decision for a treating haematologist or medical oncologist at a licensed cell therapy centre.

Scope, cell design and the trial behind each approval. Both are CD19-directed autologous CAR-T therapies made in India. Neither has ever been tested against the other. Any statement that one performs better than the other goes beyond what two separate single-arm trials are able to show, whichever direction it points in.

This is the part families are given least help with, because most of what is written about either product is written by the people who make it. Here is what the published evidence base for each approval consists of.

Two response rates sit in that table, and it is tempting to read 83.3% against 73% as a result. It is not one. The two figures come from different diseases, different patient mixes, different timepoints and different response definitions. A number measured at 90 days in adult lymphoma and a number measured at the efficacy dose across lymphoma and leukaemia together are not on the same scale.

What can fairly be said is narrower and more useful. Both products reported response rates broadly in line with what CD19 CAR-T has reported elsewhere. Both were approved by CDSCO on Indian trial data. Both are young, so the long-term record that has accumulated abroad over nearly a decade does not yet exist for either, and real-world follow-up from Indian centres is still being collected. Anyone presenting the long-term picture as settled is going past the evidence.

Clinical statements here follow published CDSCO regulatory information, the trial data published or presented for each product, and general patient-education material from bodies such as NCCN, ASCO and ESMO. No survival figure is given for either product on this page, and neither product is presented as better than the other.

By diagnosis and by centre, far more than by preference. Age and diagnosis usually leave one approved option rather than two. Where both apply, what decides it is which product the treating centre is authorised for and experienced with, when a manufacturing slot is available, and what the written estimate and financing look like.

Six questions cover the ground in the order it is usually settled. Working through them with the treating team is more useful than comparing the two products in the abstract.

1. Is CAR-T an option at all? This comes before every product and price question. Diagnosis, treatment line, organ function and disease control all decide it, and for most patients the answer is no.
2. Which product does the diagnosis and age permit? B-cell acute lymphoblastic leukaemia, or a patient aged 15 to 17, points to NexCAR19. Adult B-cell non-Hodgkin lymphoma may allow either. Ask which options are open before discussing which is preferable.
3. Which product is this centre authorised for, and how many has it given? A centre’s authorisation and its own experience with a product are legitimate parts of the answer, and they often settle the question on their own.
4. What does the written estimate include? Ask for the product, the work-up, apheresis, the admission, intensive care provision, supportive medicines and follow-up as separate lines rather than one bundled figure.
5. What is the bridging plan while the cells are being made? Manufacturing takes weeks. Ask what treatment holds the disease steady in the meantime, and what happens to money already committed if the infusion cannot go ahead.
6. How does the financing work, and who administers it? Both makers have announced financing arrangements run by third-party lenders. Ask who assesses the application, what the terms are, and what happens if treatment is cancelled.

One more thing belongs in that conversation, and it is easy to leave out. Ask what standard treatment would look like instead, including the option of not going ahead with CAR-T. A comparison against the realistic alternative is the only comparison that helps a family decide, and it is a fair question to put to any treating team.

None of these questions is unusual and none requires a confrontation. A cell therapy centre that has thought its programme through will have all six answers ready.

The pages below go further into each product, into what CAR-T costs an Indian family, and into the myeloma question that this comparison does not answer.

• NexCAR19: India’s First CAR-T Therapy Explained — how the product was developed, what it is approved for and what the reported results were.
• NexCAR19 Cost and How Families Pay for It — the published price figures and the funding routes Indian families actually use.
• CAR-T for Myeloma in India: Where BCMA Therapy Stands — why neither product on this page applies to multiple myeloma, and what does.
• Indian CAR-T vs Kymriah, Yescarta and Carvykti — how the two Indian products compare with the imported ones on cost and availability.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars, cell therapies and molecule comparisons.
• Immunotherapy at a glance — what this family of treatments does, who it is for, and who it is not for.

Editorial and referral orientation comparing two CAR-T products approved in India — not an offer, a price list, a quality ranking between named manufacturers, or a recommendation to use either product. CION Cancer Clinics does not provide, administer, stock or arrange CAR-T or any other cell therapy. All approval, availability and pricing statements are indicative and dated to August 2026, drawn from published regulatory information, manufacturer announcements and named reporting. Whether CAR-T applies to your treatment, and at which centre and with which product, is a decision for your treating haematologist or medical oncologist.